Hans Wildiers, MD, PhD
Although T-DM1 (ado-trastuzumab emtansine; Kadcyla) is already approved by the FDA as a treatment for patients with HER2-positive breast cancer previously treated with trastuzumab (Herceptin) and a taxane, findings from the TH3RESA study1
also support the regimen as a standard of care for heavily pretreated patients, explains Hans Wildiers, MD.
, Wildiers, lead author on the TH3RESA study and a professor of Medical Oncology at KU Leuven in Belgium, provides an overview of TH3RESA and discusses the trial’s significance in the field of HER2-positive breast cancer.
OncLive: What was the design of the phase III TH3RESA study?
: The TH3RESA study is a randomized study comparing T-DM1 versus a treatment of physician’s choice in patients with HER2-positive metastatic breast cancer. T-DM1 is an antibody-drug conjugate composed of trastuzumab, stably linked to a DM1 cytotoxic microtubule inhibitor. T-DM1 is already approved in HER2-positive metastatic breast cancer.
After a median follow-up of 30 months, OS improved by 6.9 months. It went from 15.8 months for patients in the control arm to 22.7 months for those in the T-DM1 arm, which was highly significant. Because of that effect, at least 50% of patients in the control arm crossed over to T-DM1 at progression.
What are the clinical implications of these findings?
The TH3RESA study confirms the EMILIA study. Both trials show that, if you use T-DM1 in patients with HER2-positive metastatic breast cancer who received a taxane and trastuzumab, T-DM1 is the preferred regimen in that setting.
... to read the full story